Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS (ORATORIO-CP)

University at Buffalo (UB)

Status: Active, not recruiting

Conditions: Primary Progressive Multiple Sclerosis

Treatments: Other: Ocrelizumab

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05974852

00007537

Details and patient eligibility

About

The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.

Full description

To study the effect of ocrelizumab on choroid plexus changes in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study

Enrollment: 732 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient participating in the ORATORIO study
• MRI scans available at baseline
• Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 3D T1-WI at baseline

Exclusion criteria

• None